News
IXHL
2.390
-6.27%
-0.160
Weekly Report: what happened at IXHL last week (0422-0426)?
Weekly Report · 6d ago
Weekly Report: what happened at IXHL last week (0415-0419)?
Weekly Report · 04/22 10:00
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 04/17 12:42
INCANNEX HEALTHCARE INC: INTENDS TO SUBMIT NDA FOR IHL-42X FIXED DOSE COMBINATION DRUG TO FDA USING 505(B)2 PATHWAY
Reuters · 04/16 12:10
Weekly Report: what happened at IXHL last week (0408-0412)?
Weekly Report · 04/15 09:56
Weekly Report: what happened at IXHL last week (0401-0405)?
Weekly Report · 04/08 09:58
Weekly Report: what happened at IXHL last week (0325-0329)?
Weekly Report · 04/01 09:57
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Weekly Report: what happened at IXHL last week (0318-0322)?
Weekly Report · 03/25 09:59
Psychedelic-Assisted Therapy Advancements Create A New Horizon For Mental Health In Colorado
Psilocybin-assisted therapy has shown promising results in treating Generalized Anxiety Disorder. The city of Denver announced a pioneering initiative to train first responders in psychedelic crisis intervention. The Heroic Hearts Project and Healing Our Heroes Foundation are at the forefront of using legal psychedelic therapy to treat veterans with PTSD.
Benzinga · 03/22 15:05
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
Weekly Report: what happened at IXHL last week (0311-0315)?
Weekly Report · 03/18 09:58
'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment
Indiana lawmakers have sent a bill to the governor's desk to fund psychedelic research. The bill includes provisions to fund studies into psilocybin as a treatment for mental health conditions. The state is one of a growing number of states pursuing reform on psychedelics. Indiana lawmakers have been considering marijuana legalization.
Benzinga · 03/14 16:42
Weekly Report: what happened at IXHL last week (0304-0308)?
Weekly Report · 03/11 09:57
Incannex Healthcare Tapped Treasurer and Controller Joseph Swan to Additional Role of CFO, Effective February 29 After Madhukar Bhalla Decided to Retire
Madhukar Bhalla, Chief Financial Officer and Secretary of Incannex Healthcare Inc. Will resign from his positions effective as of February 28, 2024. Joseph Swan, the current Treasurer and Controller of the Company, has been appointed as the Company's chief financial officer and secretary. Mr. Bhalla's decision does not reflect any disagreement with the Company.
Benzinga · 03/05 11:21
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety Disorder. The medical psychedelics field is at a pivotal juncture. Clinical trial results show potential benefits for psilocybin therapy's potential for treatment of generalized anxiety disorder. Beckley Academy has published the first open-source learning framework to advance psychedelic-assisted therapy training standards. Enveric Biosciences has signed deals to license three types of drug compounds.
Benzinga · 03/04 18:48
Weekly Report: what happened at IXHL last week (0226-0301)?
Weekly Report · 03/04 09:58
Ampio Pharmaceuticals, Ironwood, Incannex among healthcare movers
Healthcare On the Move: Avidity Biosciences, Codexis among healthcare movers. S&P 500 Health Care Sector -0.14% to 1696.29. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index. Ampio Pharmaceuticals,. Ironwood, Incannex among healthcare mover.
Seeking Alpha · 02/29 15:00
KLIC, IRWD and GRFS among pre-market losers
Seeking Alpha · 02/29 13:32
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
Psilocybin-assisted therapy shows potential benefits for Generalized Anxiety Disorder (GAD.) 44% of patients in the psilocybin group showed a clinically meaningful reduction in anxiety scores from baseline. 27% of the patients achieved full GAD remission, five times higher than the placebo group.
Benzinga · 02/28 19:33
More
Webull provides a variety of real-time IXHL stock news. You can receive the latest news about Incannex Healthcare Ltd through multiple platforms. This information may help you make smarter investment decisions.
About IXHL
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.